Abstract: In recent years, the role of glucagon-like peptide (GLP) in osteoporosis has been discovered. GLP-1 can not only increase insulin secretion, but also promote bone formation and inhibit bone resorption. GLP-2 can not only improve the intestinal barrier and promote the absorption of nutrients, but also inhibit bone resorption. This article reviews the recent studies on the regulation of GLP-1 and GLP-2 on bone metabolism, and focuses on the potential therapeutic effects of GLP-1 and GLP-2 and their related drugs on osteoporosis, with a view to exploring new ideas for the diagnosis and treatment of osteoporosis.